Perfuse Therapeutics brings Bayer an eye drug administered via an implant that controls the release of the therapy. This program is in mid-stage clinical development for glaucoma and diabetic retinopathy.
The post Bayer Sees Opportunity With $300M Acquisition of Eye Drug Biotech appeared first on MedCity News.
